G1 THERAPEUTICS INC (GTHX) Stock Price, Quote, News and Overview
NASDAQ:GTHX - Nasdaq - US3621LQ1099 - Common Stock - Currency: USD
GTHX Quote, Performance and Key Statistics
7.15
0 (0%)
The current stock price of GTHX is 7.15 USD. In the past month the price increased by 0.85%. In the past year, price increased by 481.3%.
GTHX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About GTHX
Company Profile
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. The company is headquartered in Research Triangle Park, North Carolina and currently employs 100 full-time employees. The company went IPO on 2017-05-17. The firm is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The firm's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6 inhibitors, and a Cyclin-dependent kinase 2 (CDK2) inhibitor. Trilaciclib is a novel therapy designed to transiently arrest cells that are dependent on CDK4/6 for proliferation, including hematopoietic stem and progenitor cells (HSPCs), in the G1 phase. Lerociclib is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. COSELA is a short-acting intravenous CDK4/6 inhibitor. Its CDK2 is an internally discovered inhibitor.
Company Info
G1 THERAPEUTICS INC
700 Park Offices Drive, Suite 200
RESEARCH TRIANGLE PARK NORTH CAROLINA 27709 US
CEO: John E. Bailey Jr.
Employees: 100
Company Website: https://www.g1therapeutics.com/
Phone: 19192139835
G1 THERAPEUTICS INC / GTHX FAQ
What is the stock price of G1 THERAPEUTICS INC today?
The current stock price of GTHX is 7.15 USD.
What is the ticker symbol for G1 THERAPEUTICS INC stock?
The exchange symbol of G1 THERAPEUTICS INC is GTHX and it is listed on the Nasdaq exchange.
On which exchange is GTHX stock listed?
GTHX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for G1 THERAPEUTICS INC stock?
11 analysts have analysed GTHX and the average price target is 7.29 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 7.15. Check the G1 THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is G1 THERAPEUTICS INC worth?
G1 THERAPEUTICS INC (GTHX) has a market capitalization of 377.23M USD. This makes GTHX a Small Cap stock.
How many employees does G1 THERAPEUTICS INC have?
G1 THERAPEUTICS INC (GTHX) currently has 100 employees.
What are the support and resistance levels for G1 THERAPEUTICS INC (GTHX) stock?
G1 THERAPEUTICS INC (GTHX) has a support level at 7.14 and a resistance level at 7.16. Check the full technical report for a detailed analysis of GTHX support and resistance levels.
Is G1 THERAPEUTICS INC (GTHX) expected to grow?
The Revenue of G1 THERAPEUTICS INC (GTHX) is expected to decline by -8.96% in the next year. Check the estimates tab for more information on the GTHX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy G1 THERAPEUTICS INC (GTHX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GTHX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GTHX, evaluating the profitability, health, valuation and growth aspects
- G1 THERAPEUTICS INC (GTHX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- G1 THERAPEUTICS INC (GTHX) Sales and EPS estimates to see what analysts future expectations are.
- G1 THERAPEUTICS INC (GTHX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- G1 THERAPEUTICS INC (GTHX) Insider and Institutional Ownership to learn about the owners and their transactions.
- G1 THERAPEUTICS INC (GTHX) Stock Chart to make your own analysis
- G1 THERAPEUTICS INC (GTHX) Latest news and press-releases to stay up to date.
Does G1 THERAPEUTICS INC (GTHX) stock pay dividends?
GTHX does not pay a dividend.
When does G1 THERAPEUTICS INC (GTHX) report earnings?
G1 THERAPEUTICS INC (GTHX) will report earnings on 2024-10-30, after the market close.
What is the Price/Earnings (PE) ratio of G1 THERAPEUTICS INC (GTHX)?
G1 THERAPEUTICS INC (GTHX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.86).
GTHX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GTHX. When comparing the yearly performance of all stocks, GTHX is one of the better performing stocks in the market, outperforming 99.79% of all stocks.
GTHX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GTHX. GTHX may be in some trouble as it scores bad on both profitability and health.
GTHX Financial Highlights
Over the last trailing twelve months GTHX reported a non-GAAP Earnings per Share(EPS) of -0.86. The EPS increased by 49.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.36% | ||
| ROE | -182.03% | ||
| Debt/Equity | 1.34 |
GTHX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 75% to GTHX. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 55.71% and a revenue growth -8.96% for GTHX